Tenax Therapeutics (TENX) Cash & Equivalents (2010 - 2026)

Tenax Therapeutics (TENX) has 17 years of Cash & Equivalents data on file, last reported at $118.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 6.56% year-over-year to $118.8 million; the trailing twelve-month figure through Mar 2026 stood at $118.8 million (up 6.56% YoY), and the FY2025 full-year result was $97.6 million, up 2.86% from the prior year.
• Cash & Equivalents advanced to $118.8 million in Q1 2026, from $97.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $118.8 million in Q1 2026 to a low of $2.1 million in Q4 2022.
• A 5-year average of $47.8 million and a median of $13.4 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 61.96% in 2022 and soared 1023.85% in 2025, its largest moves.
• Tracing TENX's Cash & Equivalents over 5 years: stood at $2.1 million in 2022, then soared by 361.02% to $9.8 million in 2023, then jumped by 868.66% to $94.9 million in 2024, then grew by 2.86% to $97.6 million in 2025, then advanced by 21.72% to $118.8 million in 2026.
• Business Quant data shows TENX's Cash & Equivalents at $118.8 million in Q1 2026, $97.6 million in Q4 2025, and $99.4 million in Q3 2025.